Page Loading...
Layout Table~~~~1439~1439~~
The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012~Untitled Document
Published by Visiongain, February 2007

'The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012' is a new report from visiongain providing analysis of the current and future market for IBD drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global IBD market. Autoimmune disease is a multimillion dollar market set to increase as world prevalence rates rise and the population lives longer. Inflammatory bowel disease (IBD) affect millions of people worldwide with 2.8 million currently diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD) in the US alone. The incidence of IBD is rising in developing countries around the world. Currently the global market is estimated at $16bn and this is set to continue to rise.
~Untitled DocumentPublished by Visiongain, February 2007

'The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012' is a new report from visiongain providing analysis of the current and future market for IBD drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global IBD market. Autoimmune disease is a multimillion dollar market set to increase as world prevalence rates rise and the population lives longer. Inflammatory bowel disease (IBD) affect millions of people worldwide with 2.8 million currently diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD) in the US alone. The incidence of IBD is rising in developing countries around the world. Currently the global market is estimated at $16bn and this is set to continue to rise.

Historically, management of IBD with sulphonamides and corticosteroids did little to alter the course of disease and had severe side effects. In the 1990’s new therapies were introduced in the form of enteric coated aminosalicylates (5-ASA).   From 3 drugs and one target in 1993 there are now more than 30 products and 10 targets. With the advent of monoclonal antibodies for use in IBD there has been a breakthrough in disease management which is set to expand rapidly over the next few years. Many more expensive biologicals are in the pipeline.  As they gain approval and are prescribed in favour of cheaper options, revenues in the IBD market will grow rapidly.

- Will the current monoclonal blockbuster used to treat IBD continue to grow?
- What are the hottest research drugs in the pipeline?
- Will safety of issues restrict the use of biological agents in IBD? 
Buy this report to find out!

Included in this report:

This report includes an up-to-date, analysis of IBD including the current market and possible future developments. The following important issues are covered in detail:You must order this report today.

Unique benefits to you when you order this report:
- Full searchable report when you buy the company or corporate editions
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using harddrive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables

If you buy one report this year make sure it is the report that will guarantee your success for the forthcoming years. Order this report now.

Table of Contents ~The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012 (Single user License PDF)|866|The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012 (Department License PDF)|867|The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012 (Company wide license PDF)|868|~1439~2695~~
The World Allergy Market 2006-2011: The Rx-OTC Rush~Untitled Document
Published by, Visiongain, October 2006

The number of people suffering from some sort of allergy is on the rise and the demand for reliable treatments for allergic rhinitis and other allergic conditions is on the rise worldwide. The market is a mature one with a number of high profile patent losses in the near future and a strong OTC segment. Will there be a replacement for Zyrtec or Allegra in the near Future? What role will the new improved vaccines play in the next five years? Read visiongain’s new report to find out.

~Untitled DocumentPublished by Visiongain, October 2006

Why is the World Allergies Market Important?

The number of people suffering from some sort of allergy is on the rise and the demand for reliable treatments for allergic rhinitis and other allergic conditions is on the rise worldwide. The market is a mature one with a number of high profile patent losses in the near future and a strong OTC segment. Will there be a replacement for Zyrtec or Allegra in the near Future? What role will the new improved vaccines play in the next five years? Read visiongain’s new report to find out.

What is contained in the report?

The report covers all aspects of the current allergy market, including

* A brief introduction into the biology of allergies
* A market forecast for the world prescription market 2006-2011
* Geographic breakdowns for sales revenues
* A SWOT analysis of the allergic rhinitis market
* Summaries and forecasts for the leading antihistamines and corticosteroids
* An assessment of the drivers and restraints of the market
* A discussion of the strategy of Rx-OTC switching
* A review of the OTC market for allergic rhinitis
* Analysis of treatments of eczema and allergic conjunctivitis

This report consists of over 100 pages and over 50 tables and figures.

Table of Contents ~The World Allergy Market 2006-2011%3A The Rx-OTC Rush (Single user License PDF)|899|The World Allergy Market 2006-2011%3A The Rx-OTC Rush (Department License PDF)|900|The World Allergy Market 2006-2011%3A The Rx-OTC Rush (Company wide license PDF)|901|~1439~2990~~
The World Asthma and COPD Treatment Market, 2006-2011: A Changing Market with Increasing Potential~Untitled Document
Published by Visiongain, August 2006

The asthma treatment market is a $15 billion market, driven by an increasing prevalence and yet without a treatment to cure this debilitating disease. All current drugs treat the symptoms but not the underlying cause. It is currently dominated by GSK with its $5.5 billion blockbuster, Advair/Seretide. However, this combination treatment is about to have its first real competition with Symbicort approved for the US market in July 2006. Combination drugs appear likely to dominate the mid-term forecast period as assessed by visiongain.

~Untitled Document
Published by Visiongain, August 2006

VISIONGAIN’S LATEST REPORT – ORDER YOUR COPY TODAY

The asthma treatment market is a $15 billion market, driven by an increasing prevalence and yet without a treatment to cure this debilitating disease. All current drugs treat the symptoms but not the underlying cause. It is currently dominated by GSK with its $5.5 billion blockbuster, Advair/Seretide. However, this combination treatment is about to have its first real competition with Symbicort approved for the US market in July 2006. Combination drugs appear likely to dominate the mid-term forecast period as assessed by visiongain.

Pivotal Period
However, a closer look at the potential for this market sees an approaching pivotal period, which could well see considerable change as well as additional growth. New companies are developing products with novel modes of action. The monoclonal antibodies, for so long heralded as the most significant advance the pharmaceutical industry has developed in a number of years, appear to be ready to fulfill their potential in the asthma market.

Concern
Yet there are concerns. There is currently only one available mAb for asthma treatment – Xolair. It is more expensive than other asthma drugs and is only used for patients who have difficult to control asthma. Yet the standard drug treatments are also under examination. Concern over the overuse of steroid treatments has been compounded by recent revelations of possible safety concerns over the long-term use of beta-2 agonist reliever treatments.

The dominant company in this market is GSK but it may see its position slip as new drug treatments enter the market.

Why you should buy this report:

* The asthma treatment market is large and is set to grow further.
* Generic competition is already having an impact and will having further impetus after the market-leading drug Advair/Seretide loses patent protection in 2008.
* By the end of the forecast period the leading companies will be competing with novel products.
* Monoclonal antibodies look set to achieve their potential in a market that has significant unmet needs.
* Leading drugs in the principal R&D based company pipelines are assessed.
* This report considers the latest financial and anecdotal information to enable the most appropriate choice of strategy for this market.

Table of Contents
~The World Asthma and COPD Treatment Market, 2006-2011%3A A Changing Market with Increasing Potential (Single user License PDF)|911|The World Asthma and COPD Treatment Market, 2006-2011%3A A Changing Market with Increasing Potential (Department License PDF)|912|The World Asthma and COPD Treatment Market, 2006-2011%3A A Changing Market with Increasing Potential (Company wide license PDF)|913|~1439~2997~~
World Wide C.I. CD-ROM on Autoimmune/Inflammatory Pharma Industry~
Published by Bioseeker Group, March 2005

Update your self with fresh competitive intelligence on autoimmune/inflammation drug developing industry. BioSeeker intelligence releases world-wide research on more than 400 inflammation companies and close to a thousand of drugs in development for this therapeutic area. We cover drugs from early development to registered drugs. Companies are described by all their targeted therapeutic areas and indications (not only autoimmune/inflammation), short profile, contact information, web address and email. Drugs are described by name, stage of development, mechanism and indication.~Published by Bioseeker Group, March 2005

Executive Summary

Update your self with fresh competitive intelligence on autoimmune/inflammation drug developing industry. BioSeeker intelligence releases world-wide research on more than 400 inflammation companies and close to a thousand of drugs in development for this therapeutic area. We cover drugs from early development to registered drugs. Companies are described by all their targeted therapeutic areas and indications (not only autoimmune/inflammation), short profile, contact information, web address and email. Drugs are described by name, stage of development, mechanism and indication.

The "World Wide Competitive Intelligence CD-ROM on Autoimmune/Inflammatory Pharma Industry" product is based on BioSeeker's proprietary CD-ROM technology which includes smart database structure, find and sort options, internet and email interactivity. All companies are provided with links which connect you directly to the company webpage for further research. Both companies and drugs can be further researched from inside the application by linking search queries directly to search engines like Google and PubMed. Found information on the CD-ROM may easily be shared with others over email or in print.

"World Wide Competitive Intelligence CD-ROM on Autoimmune/Inflammatory Pharma Industry" is a powerful intelligence tool for any autoimmune/inflammation drug developing company who is serious about understanding the competitive landscape they operate in and wants to acts up on it.

Facts:

* More than 400 companies covered
* More than one thousand drugs in various developmental stages included

How May This Product Be of Use?

* Find competitors, collaborations partners, M&A candidates etc.
* Jump start competitive intelligence operations
* Excellent starting point for world wide benchmarking
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/outlicensing strategy work
* Track companies over time using search engines
* Track drugs over time using search engines
* Show investors/board/management that you are right on top of industry development

All Information is Delivered to You as a CD-ROM

* Smart CD-ROM database
* Multiple search and sort functions included
* Company and drug data is linked to search engines like Google and PubMed
* Directs you directly to corporate web pages from inside the application
* Found information is easily shared with others over email or in print
* Easy to use and navigate by

System Requirements

* AMD-Athlon/Pentium II PC
* Windows 98/NT4/2000/ME/XP
* 8x-speed CD Rom drive
* SVGA 16 bit display. (32 bit recommended)
* 32 MB of available RAM (128 MB recommended)
* Internet access (to test web-enabled presentations)
~ World Wide C.I. CD-ROM on Autoimmune/Inflammatory Pharma Industry PDF Version|327| World Wide C.I. CD-ROM on Autoimmune/Inflammatory Pharma Industry%3A Hard Copy|594|~1439~1649~~
Menu Page | Toolbar Page |
Frameset Page | Index Page | Table of Contents
EROL - Electronic Retail Online E-commerce shopping cart software